US Patent Issued to TOKUSHIMA UNIVERSITY, ONCOTHERAPY SCIENCE on April 7 for "Therapeutic agent for breast cancer comprising BIG3-PHB2 interaction-inhibiting peptide derived from PHB2" (Japanese Inventors)

ALEXANDRIA, Va., April 7 -- United States Patent no. 12,595,289, issued on April 7, was assigned to TOKUSHIMA UNIVERSITY (Tokushima, Japan) and ONCOTHERAPY SCIENCE INC. (Kawasaki, Japan).

"Therapeutic agent for breast cancer comprising BIG3-PHB2 interaction-inhibiting peptide derived from PHB2" was invented by Toyomasa Katagiri (Tokushima, Japan), Tetsuro Yoshimaru (Tokushima, Japan), Akira Otaka (Tokushima, Japan), Takashi Miyamoto (Kawasaki, Japan) and Yasuhide Okamoto (Kawasaki, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides peptides containing the BIG3 polypeptide-binding site in a PHB2 polypeptide, which inhibit the binding between a PHB2 polypeptide and a BIG3 polyp...